At Beef Sommelier, we provide our B-som Diagnosis with the aim of creating a world where producers can raise their ideal cattle and consumers can enjoy beef that truly matches their preferences. Our technology not only quantifies biological information from beef cattle, but also supports producers in achieving their target meat quality. By introducing a new scientific perspective that goes beyond conventional standards, we make the “unseen qualities” of beef visible and measurable. This enables consumers to clearly understand the characteristics of the beef they choose. B-som is the world’s first scientific diagnostic service that bridges the gap between producers and consumers.
株式会社ビーフソムリエ(本社:東京都品川区、代表取締役社長:松岡俊樹)は、2025年6月18日に札幌で開催された「The JSSA Sapporo Pitch Award & Power Matching Booth Vol.60」において、ファイナリスト6...
株式会社ビーフソムリエ(本社:東京都品川区、以下:ビーフソムリエ)は、世界で一番ブランド牛に詳しくなるために、「牛肉テロワールプロジェクト」を完成させる取り組みを続けていきます。世界中の牛肉を、産...
株式会社ビーフソムリエ(以下「ビーフソムリエ」、東京都品川区、代表取締役社長: 松岡俊樹)は、一般社団法人AgVenture Lab(以下「あぐラボ」、東京都千代田区、代表理事理事長: 荻野浩輝)より資金調達を行い...
データサイエンスの力で豊かな食文化を育む、をパーパスに掲げる株式会社ビーフソムリエ(本社:東京都品川区、代表取締役社長:松岡俊樹)は、"誰もが温かく繋がるカフェ" SY.ノートCafe とともに、親子で楽しめ...
[画像1: https://prtimes.jp/i/154461/1/resize/d154461-1-8b0038abb83e6bd627d5-6.jpg ] 近畿大学生物理工学部(和歌山県紀の川市)遺伝子工学科教授 松本和也は、肉用牛の将来の肉質等を採⾎検査によって可視化...

A drug discovery venture tackling next-generation cancer treatment using marine-derived compounds that improve tumor hypoxia while minimizing side effects. Already commercialized as veterinary medicine, it supports the lives of both humans and pets.

Aortic stenosis is a life-threatening condition in which the aortic valve becomes severely narrowed. With an aging population, the number of patients is expected to increase dramatically worldwide in the coming years. Although valve replacement has become widely adopted, many patients are either too frail to tolerate the procedure or lack access to specialized treatment centers. As a result, a significant treatment gap still remains. DIVE, the device we are developing, synchronizes balloon expansion with the heartbeat to gently open the narrowed aortic valve. Its key advantage is the minimal physical burden on the patient. Through this technology, we aim to provide a safe and accessible treatment option — and ultimately save as many lives as possible.

A startup combining genome editing with smart land-based aquaculture to breed and produce high-value fish species using local resources. It aims to revitalize the fisheries industry and stabilize food supply, while contributing to lower environmental impact and regional revitalization.

Utilizing the unique genome editing technology CRISPR-Cas3, C4U develops industrial applications to combat diseases that currently have no effective treatments.